Health and Healthcare
Why Clovis Oncology Faces Some Difficulty With Its Midstage Cancer Study
Published:
Last Updated:
Clovis Oncology Inc. (NASDAQ: CLVS) shares dropped on Friday after the company announced initial data from its Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress of the European Society for Medical Oncology.
According to the study, the data show a 44% confirmed objective response rate by investigator assessment. The median duration of response in these patients has not yet been reached. Additionally, a 51% confirmed prostate specific antigen (PSA) response rate was observed in 45 PSA response-evaluable patients with a BRCA1/2 alteration.
The TRITON2 results were the basis for Breakthrough Therapy designation for Rubraca, which was granted on October 2, 2018, by the U.S. Food and Drug Administration (FDA).
While most of these results were positive, there was a downside. The most common treatment-emergent adverse events of any in all patients regardless of causality included asthenia/fatigue (44.7), nausea (42.4%), anemia/decreased hemoglobin (22.4%) and constipation (28.2%). Five patients (5.9%) discontinued therapy due to a non-progression treatment-emergent adverse event. One patient died due to disease progression.
Dr. Wassim Abida, medical oncologist, Memorial Sloan Kettering Cancer Center, and principal investigator for the TRITON2 study, commented:
Rubraca has previously demonstrated antitumor activity in its approved indications for women with advanced ovarian cancer. These new data show that Rubraca may also offer a new approach for the treatment of mCRPC associated with BRCA1 and BRCA2 alterations, with the potential to achieve a clinical response in patients with few remaining therapy options.
Shares of Clovis were last seen down about 4% at $28.86 Friday morning, with a consensus analyst price target of $62.40 and a 52-week trading range of $26.21 to $79.60.
24/7 Wall St.Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
